CliffBio
small molecule

FUSILEV

LEVOLEUCOVORIN CALCIUM

Loss of exclusivity—loss of exclusivity
CompanyAcrotech Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameFUSILEV
Active ingredientLEVOLEUCOVORIN CALCIUM
StrengthEQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2011
Marketing statusDISCN

More from Acrotech Biopharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FUSILEV patent cliff — loss of exclusivity — | CliffBio